European Commission President Ursula von der Leyen, second right, speaks with German scientist, CMO and co-founder of BioNTech Ozlem Tureci, right, Pfizer CEO Albert Bourla, left, and Belgium's Prime Minister Alexander De Croo, second left, during an official visit to the Pfizer (John Thys, Pool via AP)

October 11, 2022 11:07 AM EDTUpdated October 14, 10:38 AM

Pharma

Coronavirus

Pfizer exec denies vaccine negotiations via text message in grilling before European Parliament

Nicole DeFeudis

Editor

Amid what one member of the European Parliament called “SMS-gate,” a Pfizer executive on Monday denied that the company’s vaccine deal with the bloc could …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

TRENDING NOW

Pfizer exec denies vaccine negotiations via text message in grilling before European Parliament

Nicole DeFeudis

Editor

Sign up to read this article for free.

Among pharma CEOs, the IRA now and the IRA later get very different reactions

Bristol Myers restarts radiopharmaceutical Phase 3 trial, but delays readout by one year

Andrew Left, short seller who campaigned against Valeant, is accused of fraud by SEC

Updated: With cost-cutting underway, Bristol Myers raises guidance, touts Phase 3 win and scraps another

European drug regulator rejects Alzheimer's drug Leqembi, citing safety concerns

Critical Junctures in Gene Therapy Clinical Material Manufacturing: Where Do I Start? And Will It Work?

Pfiz­er ex­ec de­nies vac­cine ne­go­ti­a­tions via text mes­sage in grilling be­fore Eu­ro­pean Par­lia­ment

Nicole DeFeudis

Editor

Sign up to read this article for free.

Among phar­ma CEOs, the IRA now and the IRA lat­er get very dif­fer­ent re­ac­tions

Bris­tol My­ers restarts ra­dio­phar­ma­ceu­ti­cal Phase 3 tri­al, but de­lays read­out by one year

An­drew Left, short sell­er who cam­paigned against Valeant, is ac­cused of fraud by SEC

Up­dat­ed: With cost-cut­ting un­der­way, Bris­tol My­ers rais­es guid­ance, touts Phase 3 win and scraps an­oth­er

Eu­ro­pean drug reg­u­la­tor re­jects Alzheimer's drug Leqem­bi, cit­ing safe­ty con­cerns

Crit­i­cal Junc­tures in Gene Ther­a­py Clin­i­cal Ma­te­r­i­al Man­u­fac­tur­ing: Where Do I Start? And Will It Work?

Pfizer exec denies vaccine negotiations via text message in grilling before European Parliament

Among pharma CEOs, the IRA now and the IRA later get very different reactions

Bristol Myers restarts radiopharmaceutical Phase 3 trial, but delays readout by one year

Andrew Left, short seller who campaigned against Valeant, is accused of fraud by SEC

Updated: With cost-cutting underway, Bristol Myers raises guidance, touts Phase 3 win and scraps another

European drug regulator rejects Alzheimer's drug Leqembi, citing safety concerns

Critical Junctures in Gene Therapy Clinical Material Manufacturing: Where Do I Start? And Will It Work?